Peripheral Arterial Disease Clinical Trial
— HIIT_PADOfficial title:
Short-duration Aerobic High-intensity Intervals Versus Low-to-moderate-intensity Exercise Training in Symptomatic Patients With Peripheral Artery Disease: A Randomized Controlled Trial
Verified date | March 2024 |
Source | Centre Hospitalier Universitaire Vaudois |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Supervised exercise training (SET) is considered among first-line therapies for patients with symptomatic lower extremity peripheral artery disease (PAD), combined with general cardiovascular risk management, lifestyle adaptation and pharmacological treatment. Although without clear consistency, the guidelines give recommendations in terms of claudication pain severity, SET volume, duration, and frequency. However, no or little guidance is offered as far as training intensity is concerned. Most of the previous studies on SET, in the context of PAD, did not distinguish between symptom intensity and common training intensity measures such as % of maximal heart rate (%HRmax), % of HR reserve (%HRR), % of peak oxygen uptake (%VO2peak), % of VO2 reserve (%VO2R), or the rate of perceived exertion (RPE). In a recent meta-analysis, we demonstrated that both training modality and exercise intensity (based on %peak heart rate, %peak oxygen uptake, or the rate of perceived exertion) should be considered when looking for the best results in patients with symptomatic PAD. These results call for study of the individual roles of each exercise intensity and modality on walking performance and cardiorespiratory fitness in patients with symptomatic PAD. High-intensity interval training (HIIT) is composed of brief bursts of vigorous intensity interspersed with periods of rest or low-intensity exercise. HIIT may be better than moderate-intensity training (MIT) in improving cardiorespiratory fitness and functional capacity in patients with cardiovascular and metabolic diseases, but in patients with symptomatic PAD, the effects of such modalities on walking ability and cardiorespiratory fitness remain to be clearly determined. The primary objective of this study is to compare the effects of 12-week-long exercise training (short-duration high-intensity intervals vs. low-to-moderate intensity) on treadmill performance in patients with symptomatic PAD. It is hypothesized that treadmill performance would be improved to a greater extent after high-intensity exercise training
Status | Recruiting |
Enrollment | 60 |
Est. completion date | January 1, 2028 |
Est. primary completion date | July 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult patients with symptomatic PAD (Fontaine stage IIa/b); - ABI = 0.9 or drop by 20% following exercise treadmill test 1; - TBI = 0.6 if incompressible arteries (diabetes and renal insufficiency); - Signed written informed consent form. Exclusion Criteria: - Age < 18; - Unable to walk at 3.2 km/h on a treadmill (slope 0%) at least 300 m; - Previous participate in SET programs = 1 year; - Prior leg/foot amputation; - Contraindication to exercise - Neurological and neuromuscular disorders and other comorbidities (orthopedic, rheumatologic) leading to gait abnormalities. - Known Pregnancy - Incapacity of discernment |
Country | Name | City | State |
---|---|---|---|
Switzerland | CHUV | Lausanne | Vaud |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire Vaudois |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximal walking distance | Patients will perform an incremental treadmill test to determine the maximal walking distance (MWD). Initial walking speed will be set at 3.2 km/h, and at 0% grade. The grade will be increased by 2% each 2 min. | This will be assessed before and after the 3-month training program. The post-program assessment will be performed between 5 to 14 days following the last training session. | |
Secondary | Functional performance - 6-minute walk test | Patients will perform the 6-minute walk test | This will be assessed before and after the 3-month training program. The post-program assessment will be performed between 5 to 14 days following the last training session. | |
Secondary | Functional performance - ascending and descending stair performance test | Patients will perform the ascending and descending stair performance test | This will be assessed before and after the 3-month training program. The post-program assessment will be performed between 5 to 14 days following the last training session. | |
Secondary | Functional performance - short physical performance battery test | Patients will perform the short physical performance battery test | This will be assessed before and after the 3-month training program. The post-program assessment will be performed between 5 to 14 days following the last training session. | |
Secondary | Functional performance - preferred walking speed and gait analysis assessment | Patients will perform the preferred walking speed and gait analysis assessment | This will be assessed before and after the 3-month training program. The post-program assessment will be performed between 5 to 14 days following the last training session. | |
Secondary | Functional performance - unipedal stance test | Patients will perform the unipedal stance test | This will be assessed before and after the 3-month training program. The post-program assessment will be performed between 5 to 14 days following the last training session. | |
Secondary | Functional performance - 30- and 60-s repeated sit-to-stand chair test | Patients will perform the 30- and 60-s repeated sit-to-stand chair test. | This will be assessed before and after the 3-month training program. The post-program assessment will be performed between 5 to 14 days following the last training session. | |
Secondary | Cardiorespiratory fitness (VO2peak) | Patients will perform a maximal cardiopulmonary exercise test | This will be assessed before and after the 3-month training program. The post-program assessment will be performed between 5 to 14 days following the last training session. | |
Secondary | Muscle oxygenation during treadmill test | Muscle oxygenation will be assessed during treadmill test by near-infrared spectroscopy (NIRS) | This will be assessed before and after the 3-month training program. The post-program assessment will be performed between 5 to 14 days following the last training session. | |
Secondary | Hemodynamic parameters | Ankle - toe brachial index (ABI, TBI) | This will be assessed before and after the 3-month training program. The post-program assessment will be performed between 5 to 14 days following the last training session. | |
Secondary | Self-perceived quality of life and walking (dis)abilities | Self-perceived quality of life (Medical Outcomes Study Short-Form 36 (SF-36) and walking (dis)abilities (Walking Impairement Questionnaire, WIQ) will be assessed. Each questionnaire has scores on a 0-100 scale (0 (worse score) to 100 (best score)). | This will be assessed before and after the 3-month training program. The post-program assessment will be performed between 5 to 14 days following the last training session. | |
Secondary | Total amount of physical activity | The total amount of physical activity will be assessed by accelerometer. | This will be assessed before and after the 3-month training program. The post-program assessment will be performed between 5 to 14 days following the last training session. | |
Secondary | Pain-free walking distance | Patients will perform an incremental treadmill test to determine the pain-free walking distance (PFWD). Initial walking speed will be set at 3.2 km/h, and at 0% grade. The grade will be increased by 2% each 2 min. | This will be assessed before and after the 3-month training program. The post-program assessment will be performed between 5 to 14 days following the last training session. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Completed |
NCT02022423 -
Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease
|
N/A |